For more than 130 years, Abbott Laboratories has put science and innovation to work to create more possibilities for more people through the power of health. They understand that the first step to living your best life is good health.
From removing the regular pain of finger sticks as people manage their diabetes to connecting patients to doctors with real-time information monitoring their hearts, from easing chronic pain and movement disorders to testing half the world’s blood donations to ensure a healthy supply, Abbott’s purpose is to make the world a better place by bringing life-changing health technologies to the people who need them.
Abbott creates breakthrough products – in diagnostics, medical devices, nutrition and branded generic pharmaceuticals – that help individuals, their families and their community lead healthier lives, full of unlimited possibilities. Today, 113,000 employees are working to make a lasting impact on health in the more than 160 countries they serve. Their balanced leadership across diverse markets and geographies gives them more ways to grow and insulates them from the impact of global economic swings, helping them deliver consistent growth and strong shareholder returns, even in an environment as turbulent as today’s.
Focusing solely on cutting-edge innovations alone won't be enough. Their 2030 Sustainability Plan is focused on designing access and affordability into their life-changing technologies and products. Their goal is to improve the lives of more than 3 billion people by decade's end – reaching 1 billion more than they do today, each year. That will require innovating for access and affordability from the first day of research and development. They also are working across their business and in partnership with others to break down barriers and bring these innovations to the people who need them.
Abbott Laboratories Stock Details
- Ticker: nyse:abt
- Sector: Healthcare
- Industry: Medical Devices
- Market Cap: 178.59B
- Market Cap Group: Large Cap
- P/E: 34.88
- Dividend Yield: 1.98%
- Grade: B
- Dividend Aristocrat: YES
- Chowder Score: Members Only
- Revenue Growth: Members Only
- Dividend Growth: Members Only
- Dividend Growth Fit: 5/10
- Dividend Income Fit: 7/10
ABT Industry Competitors
The competitive landscape is important as they compete for the same business. Below is the list of competitors in the same industry. While not displayed, a number of metrics you can also use to evaluate your picks are the Chowder Score, the Relative Strength Index (RSI), the Graham Number, and the Piotroski F-Score.
| Ticker | Ticker | Company | Market Cap | P/E | Yield | Aristocrat | Graph | SectorID | IndustryID |
|---|---|---|---|---|---|---|---|---|---|
| ABT | NYSE:ABT | Abbott Laboratories | 178.59 | 34.88 | 1.98 | YES | 1 | 8 | 63 |
| SYK | NYSE:SYK | Stryker Corporation | 111.55 | 43.55 | 1.02 | NO | 1 | 8 | 63 |
| MDT | NYSE:MDT | Medtronics | 105.07 | 29.06 | 3.49 | YES | 1 | 8 | 63 |
Top Picks by Bay Street Experts
Expert stock analysts have shared their opinions, and sometimes prediction, on the company.
For more top picks from stock analysts on Bay Street, check the full list of top picks by expect stock analysts from investment and asset management firms.
Not all analysts are equal and they don't cover the same type of stocks. The analysts performance and ownership is tracked for comparison.
